Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children.
نویسنده
چکیده
To the editor: In a recent issue of Eurosurveillance, Kelly et al. conclude that the risks associated with the 2010 trivalent influenza vaccine from CSL Biotherapies outweighed its benefits, based on a comparison of the risk of hospitalisation due to influenza compared with that arising from an adverse reaction [1]. However the analysis is misleading and the authors’ conclusions must be considered unsound.
منابع مشابه
Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010.
Australian and New Zealand health authorities identified seasonal trivalent inactivated influenza vaccines manufactured by CSL Biotherapies as the probable cause of increased febrile convulsions in children under five within 24 hours of vaccination and recommended against their use in this age group. We quantified the benefit-risk profile of the CSL vaccines using the number needed to vaccinate...
متن کاملUpdate: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.
During the 2010 influenza season in Australia, administration of a 2010 Southern Hemisphere seasonal influenza trivalent inactivated vaccine (TIV) (Fluvax Junior and Fluvax) manufactured by CSL Biotherapies was associated with increased frequency of fever and febrile seizures in children aged 6 months through 4 years. Postmarketing surveillance indicated increased reports of fever in children a...
متن کاملNSW annual report describing adverse events following immunisation, 2010.
AIM This report summarises Australian passive surveillance data for adverse events following immunisation in NSW for 2010. METHODS Analysis of de-identified information on all adverse events following immunisation reported to the Therapeutic Goods Administration. RESULTS 424 adverse events following immunisation were reported for vaccines administered in 2010; this is 6% lower than 2009 but...
متن کاملSafety of a Trivalent Inactivated Influenza Vaccine in Health Care Workers in Kurdistan Province, Western Iran; A Longitudinal Follow-up Study
We studied the safety of a trivalent inactivated surface antigen (split virion, inactivated) influenza vaccine, Begrivac® (Novartis Company), widely used in health care workers in Kurdistan. A longitudinal follow-up study was performed in Sanandaj city, west of Iran, recruiting 936 people. A questionnaire was completed for each participant, and all symptoms or abnormal physical findings were re...
متن کاملHow did the 2008-2009 seasonal influenza vaccine affect the pandemic?
A novel influenza A(H1N1) virus appeared in Mexico in March 2009 [1]. The prototype strain, A/California/09/2009 (H1N1), was identified in April 2009, and the virus was found to have surface antigens that are distinct from those of the circulating seasonal influenza A(H1N1) virus. An early survey of antibody prevalence suggested that many persons 60 years of age might be expected to have preexi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
دوره 15 40 شماره
صفحات -
تاریخ انتشار 2010